Pfizer taps McGarryBowen on Chantix, snubs McCann

Share this article:

Pfizer passed Chantix creative work to McGarryBowen, ending McCann HumanCare's contract on the smoking cessation drug, agency sources confirmed.

The McCann consumer shop retains account duties on Pfizer's Viagra, Aricept, Detrol and Toviaz, and will continue working on Wyeth's OTC products Centrum and Caltrate, now under the Pfizer umbrella. Branded print and banner ads from McCann's Chantix campaign, featuring a tortoise and hare motif, will continue to run through the first quarter of 2009, according to Sally Beatty, director of worldwide communications at Pfizer.

Adweek reported the account shift on Friday, noting that Pfizer spent nearly $60 million marketing Chantix during the first 11 months of 2008. A spokesperson at Pfizer told Adweek that McGarryBowen “presented us with very innovative ideas that we feel best meet the needs of this brand at this time.”

McCann is part of Interpublic, and McGarryBowen was acquired by Dentsu last November.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.